Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
Stephen Checkley(AstraZeneca (United Kingdom)), Claus Bendtsen(AstraZeneca (United Kingdom))
Cited by 69
Related Papers
No related papers found
Powered by citation graph analysis